Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 40

1.

Antibody-Drug Conjugate-Based Therapeutics: State of the Science.

Birrer MJ, Moore KN, Betella I, Bates RC.

J Natl Cancer Inst. 2019 Mar 11. pii: djz035. doi: 10.1093/jnci/djz035. [Epub ahead of print]

PMID:
30859213
2.

Author Correction: 150,000-year palaeoclimate record from northern Ethiopia supports early, multiple dispersals of modern humans from Africa.

Lamb HF, Bates CR, Bryant CL, Davies SJ, Huws DG, Marshall MH, Roberts HM, Toland H.

Sci Rep. 2018 Dec 17;8(1):17993. doi: 10.1038/s41598-018-37595-3.

3.

Acute Care Surgery Model and Outcomes in Emergency General Surgery.

To KB, Kamdar NS, Patil P, Collins SD, Seese E, Krapohl GL, Campbell DS Jr, Englesbe MJ, Hemmila MR, Napolitano LM; Michigan Surgical Quality Collaborative (MSQC) Emergency General Surgery Study Group and the MSQC Research Advisory Group.

J Am Coll Surg. 2019 Jan;228(1):21-28.e7. doi: 10.1016/j.jamcollsurg.2018.07.664. Epub 2018 Oct 22.

PMID:
30359826
4.

150,000-year palaeoclimate record from northern Ethiopia supports early, multiple dispersals of modern humans from Africa.

Lamb HF, Bates CR, Bryant CL, Davies SJ, Huws DG, Marshall MH, Roberts HM, Toland H.

Sci Rep. 2018 Jan 18;8(1):1077. doi: 10.1038/s41598-018-19601-w. Erratum in: Sci Rep. 2018 Dec 17;8(1):17993.

5.

Climatic variability, plasticity, and dispersal: A case study from Lake Tana, Ethiopia.

Grove M, Lamb H, Roberts H, Davies S, Marshall M, Bates R, Huws D.

J Hum Evol. 2015 Oct;87:32-47. doi: 10.1016/j.jhevol.2015.07.007.

PMID:
26472274
6.

HSP90 Inhibitor-SN-38 Conjugate Strategy for Targeted Delivery of Topoisomerase I Inhibitor to Tumors.

Proia DA, Smith DL, Zhang J, Jimenez JP, Sang J, Ogawa LS, Sequeira M, Acquaviva J, He S, Zhang C, Khazak V, Astsaturov I, Inoue T, Tatsuta N, Osman S, Bates RC, Chimmanamada D, Ying W.

Mol Cancer Ther. 2015 Nov;14(11):2422-32. doi: 10.1158/1535-7163.MCT-15-0455. Epub 2015 Aug 13.

7.

The HSP90 Inhibitor Ganetespib Alleviates Disease Progression and Augments Intermittent Cyclophosphamide Therapy in the MRL/lpr Mouse Model of Systemic Lupus Erythematosus.

Liu Y, Ye J, Shin Ogawa L, Inoue T, Huang Q, Chu J, Bates RC, Ying W, Sonderfan AJ, Rao PE, Zhou D.

PLoS One. 2015 May 14;10(5):e0127361. doi: 10.1371/journal.pone.0127361. eCollection 2015.

8.

Archaeology. Sedimentary DNA from a submerged site reveals wheat in the British Isles 8000 years ago.

Smith O, Momber G, Bates R, Garwood P, Fitch S, Pallen M, Gaffney V, Allaby RG.

Science. 2015 Feb 27;347(6225):998-1001. doi: 10.1126/science.1261278.

9.

The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.

Smith DL, Acquaviva J, Sequeira M, Jimenez JP, Zhang C, Sang J, Bates RC, Proia DA.

Target Oncol. 2015 Jun;10(2):235-45. doi: 10.1007/s11523-014-0329-6. Epub 2014 Aug 1.

10.

Implementation of ultrasonic sensing for high resolution measurement of binary gas mixture fractions.

Bates R, Battistin M, Berry S, Bitadze A, Bonneau P, Bousson N, Boyd G, Bozza G, Crespo-Lopez O, Da Riva E, Degeorge C, Deterre C, DiGirolamo B, Doubek M, Favre G, Godlewski J, Hallewell G, Hasib A, Katunin S, Langevin N, Lombard D, Mathieu M, McMahon S, Nagai K, Pearson B, Robinson D, Rossi C, Rozanov A, Strauss M, Vitek M, Vacek V, Zwalinski L.

Sensors (Basel). 2014 Jun 24;14(6):11260-76. doi: 10.3390/s140611260.

11.

FGFR3 translocations in bladder cancer: differential sensitivity to HSP90 inhibition based on drug metabolism.

Acquaviva J, He S, Zhang C, Jimenez JP, Nagai M, Sang J, Sequeira M, Smith DL, Ogawa LS, Inoue T, Tatsuta N, Knowles MA, Bates RC, Proia DA.

Mol Cancer Res. 2014 Jul;12(7):1042-54. doi: 10.1158/1541-7786.MCR-14-0004. Epub 2014 Apr 30.

12.

The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer.

He S, Smith DL, Sequeira M, Sang J, Bates RC, Proia DA.

Invest New Drugs. 2014 Aug;32(4):577-86. doi: 10.1007/s10637-014-0095-4. Epub 2014 Apr 1.

13.

Ganetespib and HSP90: translating preclinical hypotheses into clinical promise.

Proia DA, Bates RC.

Cancer Res. 2014 Mar 1;74(5):1294-300. doi: 10.1158/0008-5472.CAN-13-3263. Epub 2014 Feb 20. Review.

14.

mTOR inhibition potentiates HSP90 inhibitor activity via cessation of HSP synthesis.

Acquaviva J, He S, Sang J, Smith DL, Sequeira M, Zhang C, Bates RC, Proia DA.

Mol Cancer Res. 2014 May;12(5):703-13. doi: 10.1158/1541-7786.MCR-13-0605. Epub 2014 Feb 19.

15.

Hominin footprints from early Pleistocene deposits at Happisburgh, UK.

Ashton N, Lewis SG, De Groote I, Duffy SM, Bates M, Bates R, Hoare P, Lewis M, Parfitt SA, Peglar S, Williams C, Stringer C.

PLoS One. 2014 Feb 7;9(2):e88329. doi: 10.1371/journal.pone.0088329. eCollection 2014.

16.
17.

Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.

Acquaviva J, Smith DL, Jimenez JP, Zhang C, Sequeira M, He S, Sang J, Bates RC, Proia DA.

Mol Cancer Ther. 2014 Feb;13(2):353-63. doi: 10.1158/1535-7163.MCT-13-0481. Epub 2014 Jan 7.

18.

Preclinical activity profile and therapeutic efficacy of the HSP90 inhibitor ganetespib in triple-negative breast cancer.

Proia DA, Zhang C, Sequeira M, Jimenez JP, He S, Spector N, Shapiro GI, Tolaney S, Nagai M, Acquaviva J, Smith DL, Sang J, Bates RC, El-Hariry I.

Clin Cancer Res. 2014 Jan 15;20(2):413-24. doi: 10.1158/1078-0432.CCR-13-2166. Epub 2013 Oct 30.

19.

Cryptic uveitis in a patient with morning glory syndrome.

Yusuf IH, Burke TR, Bates R.

Ocul Immunol Inflamm. 2014 Oct;22(5):394-7. doi: 10.3109/09273948.2013.845230. Epub 2013 Oct 21.

PMID:
24143921
20.

A rat retinal damage model predicts for potential clinical visual disturbances induced by Hsp90 inhibitors.

Zhou D, Liu Y, Ye J, Ying W, Ogawa LS, Inoue T, Tatsuta N, Wada Y, Koya K, Huang Q, Bates RC, Sonderfan AJ.

Toxicol Appl Pharmacol. 2013 Dec 1;273(2):401-9. doi: 10.1016/j.taap.2013.09.018. Epub 2013 Oct 1.

Supplemental Content

Loading ...
Support Center